Insmed Incorporated
NASDAQ:INSMBiotechnology
-$2.73 today
- Market cap
- $26.28B
- Beta
- 0.77
- P/E (TTM)
- -17.4
- EPS (TTM)
- -$5.49
Volume 1.94M
Average 3.31M
INSM EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Insmed IncorporatedNASDAQ: INSM
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA turns positive
Q2 FY2026 EBITDA was $14.16M, compared with -$297.13M a year earlier. Trailing-twelve-month EBITDA was -$770.76M.
Context
- EBITDA amounted to 193.2% of revenue in FY2025, down 31.9 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 15 analysts of -$249.4M (+78.7%) for the fiscal year ending Dec 2026, a step up from the -43.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $14.16M+110.3% QoQ
- Last fiscal yearDec 2025
- -$1.17B-43.1% YoY
- LTMJun 2026
- -$770.76M+17.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +104.8% | +84.1% | -20.7 pp |
| 1 year | -43.1% | +78.7% | +121.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (1.17B) USD
- Year-over-year change
- -43.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.17B) | -43.1% |
| FY2024 | 2024-12-31 | (818.79M) | -24.0% |
| FY2023 | 2023-12-31 | (660.18M) | -47.6% |
| FY2022 | 2022-12-31 | (447.37M) | -16.6% |
| FY2021 | 2021-12-31 | (383.65M) | — |
EBITDA vs competitors
How INSM compares with its peers on the latest reported figures
- INSM's LTM Jun 2026 EBITDA of -$770.76M is the lowest of the 4 companies compared; the peer median is $177.83M.
- Its year-over-year change of +17.8% is the 3rd highest of 4, against a peer median of +245.9%.
- EBITDA amounts to 67.8% of revenue for INSM, versus a peer median of 53.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.68B | -2.3% | +20.5% | 53.1% | |
| LTM Jun 2026 | $177.83M | +245.9% | — | 39.4% | |
| LTM Mar 2026 | $142.5M | +440.4% | — | 129.8% | |
| LTM Jun 2026 | -$770.76M | +17.8% | — | 67.8% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding INSM) | $177.83M | +245.9% | +20.5% | 53.1% | |
Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 188.46M | 245.36M | 305.21M | 363.71M | 606.42M |
| Cost of Revenue | 44.15M | 55.13M | 65.57M | 85.74M | 124.88M |
| Gross Profit | 144.31M | 190.23M | 239.64M | 277.97M | 481.55M |
| Gross Margin | 76.6% | 77.5% | 78.5% | 76.4% | 79.4% |
| Research & Development | 272.74M | 397.52M | 571.01M | 598.37M | 771.09M |
| Selling, General & Admin | 234.27M | 265.78M | 344.5M | 461.12M | 701.17M |
| Operating Expenses | 519.4M | 647.55M | 949.26M | 1.16B | 1.66B |
| Depreciation & Amortization | 14.18M | 10.33M | 10.58M | 11.01M | 16.45M |
| EBITDA | (383.65M) | (447.37M) | (660.18M) | (818.79M) | (1.17B) |
| EBITDA Margin | -203.6% | -182.3% | -216.3% | -225.1% | -193.2% |
| Operating Income | (375.09M) | (457.32M) | (709.63M) | (878.25M) | (1.18B) |
| Operating Margin | -199.0% | -186.4% | -232.5% | -241.5% | -194.0% |
| Interest Income | 174K | 11.08M | 42.13M | 53.31M | 60.66M |
| Interest Expense | 40.47M | 26.45M | 81.69M | 84.91M | 83.8M |
| Other Income / Expenses | (61.32M) | (22.83M) | (37.39M) | (31.81M) | (95.02M) |
| Income Before Tax | (436.41M) | (480.15M) | (747.01M) | (910.07M) | (1.27B) |
| Pre-Tax Margin | -231.6% | -195.7% | -244.8% | -250.2% | -209.7% |
| Income Tax Expense | (1.76M) | 1.38M | 2.56M | 3.71M | 5.03M |
| Net Income | (434.65M) | (481.53M) | (749.57M) | (913.77M) | (1.28B) |
| Net Margin | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
| EPS (Basic) | (3.88) | (3.91) | (5.34) | (5.57) | (6.41) |
| EPS (Diluted) | (3.88) | (3.91) | (5.34) | (5.57) | (6.41) |
| Weighted Avg Shares | 112.11M | 123.04M | 140.43M | 164.04M | 213.64M |
| Weighted Avg Shares (Diluted) | 112.11M | 123.04M | 140.43M | 164.04M | 213.64M |
Insmed Incorporated
NASDAQ:INSM
Intrinsic Alpha fair value
Locked
Current Price
$119.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.